Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Cinieri, Saverio; Chan, Arlene; Altundağ, Kadri̇; Vandebroek, A.; Tubiana-Mathieu, Nicole; Barnadas, Agustí; Dodyk, Patricia; Lazzarelli, Silvia; Botha, Michiel; Rauch, Daniel; Villanova, G.; Coşkun, Uğur

doi:10.1016/j.clbc.2016.06.014

Cited by 12 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, there was no evidence that the NORCAP regimen had a detrimental effect on quality of life. Therefore, it was concluded that all-oral NORCAP is an active first-line chemotherapy regimen which may be offered as an alternative to first-line taxane-based therapy for HER2-negative MBC, especially for patients who wish to avoid alopecia or frequent IV administrations [88]. An open-label, prospective, randomized, controlled Phase III trial (Success-A study) assessed the toxicity profile when gemcitabine is added to adjuvant taxane-based chemotherapy in high-risk EBC patients.…”

Section: Therapeutic Combinations In Breast Cancermentioning

confidence: 99%

Drug Combinations in Breast Cancer Therapy

Fisusi

Akala

2019

PNT

305

163

View full text Add to dashboard Cite

Breast cancer therapy involves a multidisciplinary approach comprising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with minimal undesirable effects to ensure a good quality of life for patients. The carefully selected combination of therapeutic interventions provides patients with the opportunity to derive maximum benefit from therapy while minimizing or eliminating recurrence, resistance and toxic effects, as well as ensuring that patients have a good quality of life. This review discusses therapeutic options for breast cancer treatments and various combinations that had been previously exploited. The review will also give an insight into the potential application of the nanotechnology platform for codelivery of therapeutics in breast cancer therapy.

show abstract

Section: Therapeutic Combinations In Breast Cancermentioning

confidence: 99%

Drug Combinations in Breast Cancer Therapy

Fisusi

Akala

2019

PNT

305

163

View full text Add to dashboard Cite

show abstract

“…Figure shows the study selection process. Among the 20 studies, 11 were randomized phase II trials, and 9 were randomized phase III trials . Three trials were three‐armed trials, and the other 17 had two arms.…”

Section: Resultsmentioning

confidence: 99%

Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis

et al. 2019

View full text Add to dashboard Cite

STUDY OBJECTIVES To compare the effectiveness of different taxane-containing regimens and to identify the best strategy for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). DESIGN Network meta-analysis of 20 randomized controlled trials (RCTs). PATIENTS A total of 6577 patients with HER2-negative MBC who received treatment (20 different regimens) with taxanes (paclitaxel [4267 patients] or docetaxel [2310 patients]). MEASUREMENTS AND MAIN RESULTS The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched (through March 2019) for RCTs that evaluated any taxane-containing regimens for the treatment of HER2-negative MBC. A network meta-analysis in a Bayesian framework was performed using the random-effects model. We compared the surface under the cumulative ranking (SUCRA) curve for each regimen. Overall, paclitaxel-based combinations were superior to paclitaxel alone in objective response rate (ORR) (odds ratio 1.60, 95% credible interval [CrI] 1.15-2.16) and overall survival (OS) (hazard ratio 1.08, 95% CrI 1.01-1.15). Docetaxel-based combinations were also superior to paclitaxel alone in ORR. Among the paclitaxel-based regimens, based on the results of SUCRA, paclitaxel + bevacizumab + capecitabine was likely to be the most efficacious in improving ORR, OS, and progression-free survival (PFS), whereas paclitaxel + gemcitabine was likely to be the most efficacious in 1-year OS rate. Among the docetaxel-based a These authors contributed equally to this work.regimens, based on the results of SUCRA, docetaxel + gemcitabine was likely to be the most efficacious in improving PFS and OS. CONCLUSION These findings demonstrated that paclitaxel-based combinations can provide significant improvement in ORR and OS compared with paclitaxel alone. The regimens of paclitaxel + bevacizumab + capecitabine, docetaxel + gemcitabine, and paclitaxel + gemcitabine may be superior to other regimens for the treatment of HER2-negative MBC. KEY WORDS taxanes, paclitaxel, docetaxel, metastatic breast cancer, network meta-analysis.

show abstract

“…The DCRs were 73.5% with oral vinorelbine plus capecitabine, 78.0% with gemcitabine plus paclitaxel, and 80.0% with gemcitabine plus docetaxel. [23] Although the oral chemotherapy indicated a slightly lower DCR than intravenous chemotherapy,…”

Section: Oral Vinorelbine Plus Capecitabine In Breast Cancermentioning

confidence: 97%

Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic

Bi-cheng¹,

Xiao²

2022

jbyyj

View full text Add to dashboard Cite

The novel coronavirus has a significant impact on the routine clinical practice for cancer patients in China since December 2019. During the epidemic in mainland China, especially Wuhan, the intravenous chemotherapies of cancer patients were considerably delayed. Up to now, cancer patients throughout the world directly encounter similar obstacles. For patients who have the right to choose chemotherapeutic regimens with different administration routes, oral drugs can be considered to be applied. In this mini-review, oral chemotherapeutic drugs were compared with intravenous drugs in seven types of tumors. Accordingly, we intended to provide useful suggestions for clinicians to balance the benefits and risks of oral against intravenous chemotherapies and to choose properly substituted oral chemotherapeutic regimens for cancer patients amid the coronavirus disease 2019 (COVID-19) pandemic.

show abstract

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer

Cited by 12 publications

References 22 publications

Drug Combinations in Breast Cancer Therapy

Drug Combinations in Breast Cancer Therapy

Comparative Effectiveness of Taxane‐Containing Regimens for Treatment of HER2‐Negative Metastatic Breast Cancer: A Network Meta‐analysis

Oral Versus Intravenous Chemotherapy in COVID-19 Epidemic

Contact Info

Product

Resources

About